Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
October 15 2021 - 8:21AM
Dow Jones News
By Colin Kellaher
Merck & Co. and Eisai Co. on Friday said the European
Medicines Agency's Committee for Medicinal Products for Human Use
recommended approval of the combination of Eisai's Lenvima and
Merck's Keytruda in two new cancer indications.
Merck, based in Kenilworth, N.J., and Tokyo-based Eisai said the
CHMP recommended approval of the combination as a first-line
treatment of adults with advanced renal cell carcinoma.
The committee also backed the combination for adults with
advanced or recurrent endometrial carcinoma who have disease
progression on or following prior treatment with a
platinum-containing therapy in any setting and aren't candidates
for curative surgery or radiation advanced endometrial
carcinoma.
The European Commission, which generally follows the CHMP's
advice, will now review the recommendations, with decisions
expected by the end of the year.
Eisai and Merck in March 2018 formed a collaboration to jointly
develop, manufacture and commercialize Lenvima as monotherapy and
in combination with Merck's blockbuster cancer drug Keytruda.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 15, 2021 08:06 ET (12:06 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From May 2024 to Jun 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jun 2023 to Jun 2024